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Development of Animal Drugs for Market 
Presented Before the Iowa Academy of Science, April 21 , 22, 1967 
The complexities of modem scien-
tific knowledge have vastly increased 
the requirements for the clearance of 
an animal drug for market. All such 
drugs, which include those for poul-
try, are subject to the regulations of 
the Food and Drug Administration 
(FDA). The data obtained in the de-
velopment studies must convince the 
FDA examiners that the drug is both 
safe and effective. To accomplish this, 
numerous disciplines are involved, 
such as parasitology, microbiology, 
pharmaceutical formulation, nutrition, 
animal management, organic chemis-
try, analytical chemistry, biochemis-
try, pharmacology, pathology, veterin-
ary medicine, chemical engineering, 
and statistics. Thus, the desired prod-
uct can only be obtained by a team 
approach. In our laboratory there are 
four teams involved; the first finds an 
effective drug, the second evaluates 
its safety, the third evaluates its ac-
tion in field tests, and the fourth pro-
duces the drug in quantity. 
Product development is expensive, 
yet new products are essential to a dy-
namic industry. Because of the costs, 
all product development must be 
carefully evaluated by management. 
The market is determined, selling 
price estimated, and the cost of re-
search, development, and production 
evaluated. Only then can a decision 
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be made concerning the potential of 
the product. Some products, such as 
those for poultry, must be marketed at 
a very low cost, for the total cost of 
medication and vaccination should 
not be greater than three cents per 
broiler chicken. 
The challenge of drug development 
is that it is the result of someone's 
idea. As the idea is developed, other 
ideas occur so that one is working in 
a thought-provoking environment and 
continually subjected to the stimulus 
of problem-solving. There is a great 
satisfaction when the product is mar-
keted. 
The initial testing of a substance or 
compound may be simply a blind 
screen, that is, testing the material for 
activity on the basis of its availability. 
However, in the writer's experience, 
he selected first those compounds 
which, from their chemical structure 
and from knowledge of the scientific 
literature, he judged to be most likely 
to have activity. The organic chemist 
also enters into this picture, for he 
may have conceived of a chemical, 
synthesized it, and submitted it for 
testing. Once some degree of activity 
has been determined, then the biolo-
gist and chemist can work together in 
molecule manipulation, that is, chang-
ing the position of a moiety or substi-
tuting other moieties on the basic 
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structure. For example, when the 
writer was doing this work and found 
activity for organotin compounds as 
anthelmintics, he examined 125 of 
these compounds. The best of these 
was selected for a product, and excel-
lent patent coverage was obtained for 
the series. Other biologists then tested 
a number of the compounds for ac-
tivity against other disease-causing or-
ganisms. 
The next step is the establishment 
of all ways in which the compound 
may be used, i.e., for treatment, for 
preventj_on, administered as a tablet, in 
the feed, in the drinking water, or by 
injection. Not only must the amount 
be established, but also the length of 
time it will be administered. Since 
few · drugs are administered as the 
compound per se, it is necessary to 
formulate it into a product. If it is to 
be a tablet, suitable binders or other 
ingredients must be found. If it is to 
be administered in drinking water, it 
may have to be incorporated with 
solubilizers or pH controlling agents. 
A product to be mixed in feed usually 
consists of the compound and some 
suitable feed ingredient which will 
permit thorough distribution in the 
final feed. An injectable product must 
not be more than transiently irritat-
ing. In each dosage form, the eff ec-
tiveness of the product must be clear-
ly defined. 
The studies to this point have re-
quired a considerable quantity of com-
pound. Usually the organic chemist 
has been supplying it from syntheses 
in his laboratory. This has provided 
the opportunity to try different pro-
duction procedures and from this ex-
perience he has reached a decision as 
to the most economical method of pro-
duction in the chemical plant. This 
work has also permitted better defini-
tion of the physical and chemical 
properties and methods of purifica-
tion. Identification of the contami-
nants which may be present is also 
important. 
At this point, another team takes 
over the production of the compound. 
This team consists of production chem-
ists and chemical engineers who de-
termine how to adapt the procedure 
recommended by the organic chemists 
to the production facilities. This is 
usually done through a pilot plant 
process where it is determined what 
effects reaction conditions have upon 
yield when pound batches of the 
chemical are produced. The quality of 
the chemical must be continually 
checked. As experience is gained, the 
type of equipment required for larger 
batches and the economics of the 
process are worked out. These studies 
finally permit the definition of the 
specifications for the compound, that 
is, its purity, and physical and chemi-
cal characteristics for identification. 
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In our institution, analytical chemis-
try is tied in with the safety team. 
These chemists have been involved in 
developing a method of analysis and 
the more specific the method, the bet-
ter it is considered to be. Three meth-
ods of analysis may be necessary, one 
for the compound itself, one for the 
compound incorporated in the prod-
uct, and one for the final dosage form 
if that form is feed or drinking water. 
The last method requires the greatest 
sensitivity because the dosage may be 
as low as 50 ug per gram of medium. 
The final dosage form method of 
analysis must also be studied for pos-
sible interfering substance, such as 
other drugs which are used in feeds , 
which may be included by chance or 
accident. This knowledge is very help-
ful in the quality control of the final 
dosage form. The first two types of 
methods are supplied to the quality 
control section of the production team 
and the third is made ready for the 
eventual customer. 
When methods and formulated 
product are available, the analytical 
chemist initiates stability studies on 
the product and, if applicable, the 
final dosage form in feed or drinking 
water. These are subjected to various 
environments and analyses made at 
definite intervals over at least a six-
month period to determine whether 
changes in quantity have occurred. 
Also, many feeds are pelleted, so it 
must be shown that this process does 
not change the content of the com-
pound. 
When sufficient compound is avail-
able and the dosage has been estab-
lished, safety studies are initiated in 
animals. The first of these are de-
signed to determine the safety of the 
product for the animals on which it is 
to be used. The types of safety tests 
which may be done are: acute toxici-
ty, which are short-term; subacute 
toxicity, which are ninety days in dur-
ation or for the lifetime of a short-
lived animal ( broilers, turkeys ); 
chronic toxicity, which are two-year 
tests; and reproduction tests to en-
sure that the compound has no effects 
on this phase of life. In most of these 
tests, it is desirable to determine the 
maximum dose which has no harmful 
effect ( the no-effect dose) and the 
maximum tolerated dose, or that dose 
which harms, but is not lethal. 
Acute toxicity studies are done pri-
marily on compounds in products 
which are used for treatment of dis-
ease and particularly those which will 
be used for only a few days. This test 
involves the determination of the sin-
gle oral dose which will be lethal to 
50 per cent of the test animals (LD50) . 
The acute toxicity of compounds to be 
given to large animals is determined 
in laboratory animals. The LD50 is 
used because it is the most easily re-
produced and is actually established 
by means of a statistical manipulation. 
From this a therapeutic index is de-
rived, that is, the ratio between the 
LD50 and the therapeutic dose. The 
greater the ratio, the greater the prob-
ability of safety. It is also very help-
ful if one can determine by this test 
the organs most affected by an exces-
sive dosage. 
The subacute toxicity test is of par-
ticular value for compounds which are 
given for weeks or months. Such com-
pounds are usually incorporated in 
disease-preventive or growth-promot-
ing types of products. In this test, a 
series of dosages covering a wide 
range are continually administered 
and are started during the growth 
phase. The minimum length is ninety 
days, but it may be extended to the 
normal market age of the animal. Suf-
ficient numbers of individually housed 
animals of both sexes are used in each 
dose level to permit a valid statistical 
evaluation of effects on growth and 
feed consumption. During the test, 
hematologic studies are made periodi-
cally and a number of other biochemi-
cal tests may be conducted. All ani-
mals dying during the test are ex-
amined, and at the end of the test all 
are killed and examined for gross 
pathology. Samples of approximately 
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thirty tissues are taken for microscopic 
evaluation by a pathologist. The prod-
uct is considered to be safe for the 
animals if the maximum no-effect 
dose is at least three times the use-
dose of the compound. 
Because the safety for man is part 
of the evaluation, the same type of 
test is also conducted in rats or mice 
and dogs. These tests are ninety days 
in duration. If the maximum no-effect 
dose and the maximum tolerated dose 
are approximately the same in the two 
species, toxicologists assume that man 
can detoxify the compound in ap-
proximately the same manner and a 
potential hazard for man can be es-
tablished. 
During this time, biochemists have 
also been at work to determine wheth-
er the compound is metabolized by 
the animals and, if so, what the princi-
pal metabolites are. A method of anal-
ysis for these must be developed so 
that the amount of residue in the ma-
jor consumable tissues can be deter-
mined. The sensitivity of the method 
depends on the toxicity of the drug. A 
drug which has a wide margin of 
safety, i.e., a low order of toxicity, 
does not require as sensitive a meth-
od, while one with a narrow margin 
of safety requires greater sensitivity. 
A rule of thumb in our laboratory is 
sensitivity and accuracy to less than 
0.1 ug per gram of tissue. Methods 10 
to 100 times this sensitivity are in use 
today. The sophistication of the meth-
od usually involves some type of chro-
matography and the use of sensitive 
electronic devices, e.g., gas chromato-
graph, spectrophotometer, polaro-
graph. When the method is available, 
then the rate of disappearance of the 
residue following the withdrawal · of 
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the drug is established. This provides 
evidence for determining how long 
before slaughter for human consump-
tion the drug must be withdrawn. If 
applicable, the occurrence of the resi-
due in milk or eggs is also made and 
if any is found, the product can be 
used only in such a manner that the 
milk or eggs containing residue will 
not be consumed by man. In this man-
ner, man is protected from a possible 
hazard in his food. 
If a residue exists and it is desirable 
to give the product until slaughter of 
the animal for human food, then pres-
ent FDA requirements are that the 
compound must be subjected to a 
chronic toxicity study in rats or mice 
and dogs. In our laboratory, in addi-
tion, we conduct such tests in chick-
ens. Except for dogs, the size of each 
treatment group must be large enough 
to permit adequate data at the end of 
the test for statistical evaluation. A 
current test was started with a total of 
1,200 mice and another test with 400 
rats, each individually caged. The dos-
ages used may be governed by the 
highest tissue residue found while the 
animals are receiving medication. The 
residue in meat may be considered to 
be safe for man if 100 times its quan-
tity is safe for the test animals when 
given throughout the two years of test. 
Food consumption is measured 
throughout the test because it meas-
ures the dosage since the compound is 
incorporated in the feed. Body weights 
are taken at weekly or biweekly in-
tervals. Periodic hematologic exam-
inations are performed and enzyme 
studies may be conducted. Each ani-
mal which dies must be examined at 
post-mortem and tissues taken for his-
tologic examination . At the termina-
tion of the test, all of the survivors are 
killed, examined for gross pathology, 
and tissues from a proportion are sub-
jected to microscopic examination by 
a pathologist. This type of test also 
determines whether the compound 
may be cancer-inducing in the rodent. 
The fourth team involved in the de-
velopment of a drug is the clinical 
team. Before the drug can be cleared, 
it must be subjected to testing in the 
field. This cannot be done until ef-
fectiveness has been shown, safety 
studies have been completed, and the 
tissue residues and the rate of their 
depletion established to the satisfac-
tion of the FDA. Thus, when the ani-
mals go to market, there will be no 
potential hazard for man. The pur-
pose of this testing is to determine 
both the safety and effectiveness of 
the use dose under diverse conditions. 
To accomplish this, the testing is car-
ried out in about half a dozen differ-
ent geographic locations during differ-
ent seasons of the year. A considerable 
number of animals are used at each 
location and in the different seasons. 
With broiler chickens, this may total 
to several hundred thousand birds. 
During the course of these tests, peri-
odic examinations are made of the 
group undergoing medication for ef-
fectiveness of the drug and for any 
unpredicted reactions. If the animals 
are slaughtered for human consump-
tion, they are followed through the 
packing house and the carcasses ex-
amined. If the product is a disease 
preventive, it must be shown that the 
test animals were exposed to the dis-
ease. A product successful in these 
tests should be successful on the mar-
ket as far as safety and effectiveness 
are concerned. 
The extensive and intensive work 
required for the development of a 
product for market clearly shows why 
a team approach is the only practical 
approach. Judicious management pro-
cedures must coordinate and correlate 
the many scientific disciplines in-
volved. One important aspect not pre-
viously mentioned is the necessity of 
clear, concise, well-organized and 
readily understandable reports of the 
testing so that others, particularly the 
FDA officials, can easily conclude 
whether the product is safe and ef-
fective. It should be readily under-
stood that a number of years are in-
volved in completing the development 
of a drug. If no serious difficulties are 
encountered, the shorter-term phases 
of development can be completed in 
approximately two and a half years . 
With luck and good planning, the en-
tire testing takes four years, but our 
experience has shown that five years 
are frequently required. 
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The whole procedure of drug de-
velopment is very challenging. When 
it is accomplished, those involved de-
rive much satisfaction, particularly 
when the marketing personnel are suc-
cessful in selling the product and the 
need of a customer is fulfilled. One 
also has the satisfaction of knowing 
that he has made a contribution to the 
food supply for man, a contribution 
which by modern methods of evalua-
tion will not add to the potential haz-
ards encountered in man's daily life. 
